News & Updates

Treatment with two or four intra-articular injections of platelet-rich plasma confers stable clinical improvements in patients with knee osteoarthritis (OA) but has no demonstrable impact on the levels of synovial cytokine and growth factors, a recent study has found.

The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.

Though decreasing over time, early mortality remains high in patients with multiple myeloma (MM), a recent study has found. Important risk factors include older age, a more aggressive disease, and a patient’s poor physical condition.